



BEYOND SOUND SCIENCE, CUTTING-EDGE TECHNIQUES ASSOCIATED WITH RELEVANT DISEASE MODELS AND A COMPREHENSIVE BACKGROUND OF PHYSIOPATHOLOGY, WE OFFER ROBUST EFFICACY DATA AND HIGH VALUE INTERPRETATION, **TO ANTICIPATE CLINICAL EFFICACY**

CONTENTS

The bottleneck in Drug Discovery	3
Syncrosome's Preclinical Offer	4
In short	5
Drug Efficacy services	6
Key facts	7
Bioavailability and CNS-PK	9
Testimonials	10
Some of our references	11
Contact us	12

As more **than 60% of new drugs fail in phase 2**, we have chosen to focus our activities since 2000 on **preclinical In Vivo Efficacy Studies** to offer better predictability and anticipate clinical results. We are actively involved in optimizing **efficacy study designs** on animal models to improve the success rate in phase 2 and thus reduce **the drug-to-market cost**.

Syncrosome combines several skills and scientific competencies and look forward to assist our customers in evaluating the **potential of their compounds**.

RICHARD MITRY

Founder & CEO

SYNCROSOME

IN SHORT

Partner of large and medium drug discovery companies all around the world since 2000, our main activities consist in :

DRUG EFFICACY STUDIES BIOAVAILABILITY AND CNS-PK STUDIES


We have developed and validated so far more than 15 disease models, and our flexible and human-sized organization can design and operate tailored experimental protocols to give you appropriate answers.

We base our approach on a team of experts and Study Directors with people having **a large scientific experience** coming from Pharma's, Biotechs and Academic research.

OUR PRECLINICAL SERVICES


PHYSIOLOGICAL BIOMARKERS

Cardiovascular monitoring, Inflammation, Neuroprotection, Respiratory monitoring, Behaviour tests, Gastrointestinal activity




FUNCTIONAL EXPLORATION

Echocardiography, Plethysmography, Laser doppler, Fluorescence microscopy, Image analysis




DISEASE MODELS



ELISA, Histology, Enzyme activity, Cell counting, Bioanalytical services, Neuromediator monitoring


CELLULAR AND MOLECULAR BIOMARKERS



Special administration, Surgery suites, Microdialysis, PK and Bioavailability, Accredited vivarium, In vivo BBB passage

IN VIVO EXPERIMENTS


DRUG EFFICACY STUDIES




Central nervous system :
Parkinson, Stroke, (CNS PK)



Gastroenterology :
IBD, IBS, Ulcer, Emesis and/or Nausea, Intestinal transit, Gastric emptying



Cardiovascular :
Arterial hypertension, Acute myocardial ischemia, Heart failure, Blood loss



Metabolic Disorder :
Type 1 Diabetes, Type 2 Diabetes



Respiratory :
Asthma, Bronchitis, Cough, Pulmonary Arterial Hypertension

PHARMACOKINETICS AND CNS-PK

CNS- PK

- BBB passage
- Brain to plasma ratio
- Neurotransmitter concentration
- Brain microdialysis

PK supporting efficacy assessment

- Bioavaililbilty from rodent to NHP
- Bioanalysis
- Various administration routes and organe or fluid sampling

KEY FACTS

- › Founded **in 2000**, owner of its facilities (lab, housing and offices)
- › Based in Marseille (3 hours away by train from Paris)
- › Near international airport Marseille Provence and Toulon airport with transportation.
- › More **than 350 studies** carried so far, **180 customers**.
- › **Accredited facilities** (N°B-1305529), laboratory and technical staff.
- › Member of **the French Ethical Committee** C2EA – 71
- › **CIR Agreement**

TESTIMONIALS

We were looking for a few months for a company able to help us in making the right decision with our in house compounds.

Our discussions with Syncrosome were very fruitfull and were always available to give us their feedback and suggestions. They are focus on in vivo efficacy studies for more than 10 years with a comprehensive background. In summary « good procedures for good science »

allowed us to succed in phase 2. Very good guys, thank you !

M.T., Target Validation, CHIESI Farmaceutici S.p.a.

We wanted to collaborate with a high level CRO capable of conducting in vivo studies in a good scientific manner, and to assist us in elaborating the study design and interpretation of results. We retained Syncrosome after visting their facilities that they fully own. We also audit their procedures, SOP, training program etc... Everything was OK. We had very good relationship with the Study director and good discussions before, during and after the experiments !

C.P. Director Research and Preclinical, HELSINN

SOME OF OUR REFERENCES



KEEP IN MIND...

- 15 **disease models** in Several therapeutic areas, validated in house.
- Additionnal parameters and Biomarkers analysis, for **High Content Data**.
- **Bioavailability** and **CNS-PK** studies.
- Development of **customized models** with validation steps.
- Proactive approach in study design, experimental stage and **data interpretation** with dedicated study directors for each Dpt.
- **GLP-like** laboratory

To optimize your preclinical strategy with High Content Data Experiments and give more chance to your compounds.



CAMPUS LUMINY - LUMINY ENTREPRISES CP 908

163, Avenue de Luminy 13288 MARSEILLE - France

Phone : +33 495 053 180 - Fax : +33 495 053 185

dvpt@syncrosome.com - www.syncrosome.com

